| Description | The anti-malignancy variant receptor (MVR) monoclonal antibody that specifically recognizes B cell lymphoma cells, a membrane permeable domain. The anti-MVR antibody showed the highest reactivity with JVM2, SNU538, and LCL among the six B cell lymphomas, while the BC1 and SNU20 cells showed low reactivity. The flow cytometry analysis showed that the mAb showed strong reactivity with various types of B cell lymphoma cells but did not react with CD4 + T cells, CD8 + T cells, and CD14 + monocytes containing normal CD19 + B cells and any other lymphocytes. |
| Clonality | Monoclonal |
| Host Species | Human |
| Target Species | Human |
| Immunogen | L3055 cell lines |
| Epitope | A membrane permeable domain of malignancy variant receptor (MVR) protein |
| Isotype | IgG1 kappa |
| Expression Species | HEK293F or CHO |
| Conjugation | None |
| Purity | >95%, determined by SDS-PAGE and SEC-HPLC |
| Endotoxin | <1 EU/mg |
| Purification | Protein A affinity purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4°C within a week. For longer storage, aliquot and store at -20°C. |
| Application | FC; WB; FuncS |
| Application Notes | The antibody is recommended for detection of B cell lymphoma by FC, WB (1/1000-1/5000), FuncS assays. |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
| Target | MVR |
| Alternative Name | MVR, malignancy variant receptor, B cell lymphoma cells |
| Research Area | Immunology |
